mechanisms of action. In so doing, we can look forward to entering the era of personalized medicine in FL.

Conflict-of-interest disclosure: The author declares no competing financial interests.

REFERENCES

DOI 10.1182/blood-2016-12-753145 © 2017 by The American Society of Hematology

PLATELETS AND THROMBOPOIESIS

Comment on Sivapalaratnam et al, page 520

Parsing the repertoire of GPIb-IX-V disorders

A. Koneti Rao and Natthapol Songdej LEWIS KATZ SCHOOL OF MEDICINE AT TEMPLE UNIVERSITY

In this issue of Blood, Sivapalaratnam et al1 report an association between unique, rare monoallelic variants in GP1BB, which encodes the glycoprotein (GP)Iββ subunit of the platelet GPIb-IX-V complex, and autosomal dominant macrothrombocytopenia.

Platelet GPIb-IX-V is a major player in hemostasis, serving as the receptor for von Willebrand factor (VWF) and mediating the platelet–subendothelium interactions. Deficiencies of this multiprotein complex or the plasma VWF result in a bleeding diathesis. The GPIb-IX-V complex, expressed on megakaryocytes and platelets, contains 4 distinct transmembrane subunits, GPIbα, GPIbβ, GPIX, and GPV (see figure). Each subunit is a distinct gene product. The best recognized inherited bleeding disorder involving the GPIb-IX-V complex is the Bernard-Soulier syndrome (BSS), an autosomal recessive disorder arising from homozygous or compound heterozygous variants of GPIbA, GPIbB, and GP9. In 1948, 2 French physicians, Jean Bernard and Jean-Pierre Soulier, first reported a severe bleeding disorder associated with thrombocytopenia and giant platelets, later shown to be characterized by decreased ristocetin-induced platelet agglutination. To date, 45, 39, and 28 variants in GPIBA, GPIBB, and GP9, respectively, have been identified in the BSS. GPI5 variants have not been implicated in the BSS. In contrast to these loss-of-function variants, some GPIBA variants have conferred an increase in affinity of the platelet complex for VWF, resulting in the platelet-type vWD associated with a secondary decrease in plasma high molecular weight VWF multimers. More recently, an association between monoallelic variants in GPIBA and an autosomal dominant macrothrombocytopenia has emerged (see figure).

The most frequent of these is the GPIBA variant (p.Ala172Val), labeled as the “Bolzano” variant, associated with mild thrombocytopenia and increased platelet volume, with or without mild bleeding symptoms. Three other monoallelic GPIBA variants have also been implicated. Although GPIBB variants have been linked to autosomal dominant macrothrombocytopenia in 3 Japanese families, this association is not well established.

Sivapalaratnam et al extend the repertoire of GPIb–IX–X complex-related disorders by documenting a statistical association between rare nonsynonymous monoallelic variants in GPIBB and autosomal dominant macrothrombocytopenia. Their approach used high-throughput whole-genome DNA sequencing coupled with human phenotype ontology coding of clinical and laboratory phenotypes. The study population consisted of 1 discovery and 2 validation cohorts. The discovery cohort comprised 1542 patients with a suspected inherited bleeding or platelet disorder with unknown molecular etiology, or their relatives, enrolled in the National Institute for Health Research BioResource. One validation cohort contained 75 patients with thrombocytopenia evaluated with the ThromboGenomics gene panel, whereas another contained 301 patients from a Japanese cohort with suspected inherited thrombocytopenia and their relatives. Within the discovery cohort, there was a strong association identified between rare (allele frequency <1/10 000) nonsynonymous monoallelic GPIBB variants and macrothrombocytopenia, with a family history suggestive of autosomal dominant inheritance. Eight probands with GPIBB variants were identified from the discovery cohort; they did not have other genetic variants previously implicated in macrothrombocytopenia. In the validation cohorts, 10 further GPIBB variants were identified, for a total of 18 probands (27 total cases), with 9 distinct GPIBB variants across cohorts.

Patients with GPIBB variants had platelet counts ranging from 47 to 172 × 10^9/L (mean, 108 × 10^9/L) and increased platelet volumes (10.7–14.3 fL; mean, 12.74 fL). Macrothrombocytopenia was defined as a platelet count below 150 × 10^9/L and mean platelet volume above 12 fL. Patients with platelet anisocytosis with a subset of abnormally large platelets were also considered...
to have macrothrombocytopenia, emphasizing the importance of recognizing the heterogeneity in platelet size. Bleeding symptoms were observed in 9 of 23 female patients, but not in any of the 8 male patients from whom information was available, indicating that bleeding diathesis is mild, if at all discernible. Although no information is presented regarding platelet function, 8 of 9 family members studied showed a reduction of at least 30% in platelet GPIbα by flow cytometry, a level of deficiency unlikely by itself to markedly impair platelet agglutination by ristocetin.

These studies extend the rapidly increasing list of genes implicated in inherited thrombocytopenias. Specifically, they document a clinically detectable autosomal dominant macrothrombocytopenia phenotype in association with variant GP1BB genotype. Relevant to note, most obligate carriers of biallelic BSS do not appear to have deranged platelet size or number and are asymptomatic, although this premise is ripe for a careful second look. The GP1BB variants identified by Sivapalaratnam et al may have a dominant negative effect, which is yet to be demonstrated.

From a clinical viewpoint, GP1BB variants need to be considered in the context of an unexplained inherited or chronic macrothrombocytopenia. Studies from the International Consortium focusing on 211 unrelated families with BSS reiterate that even in patients with biallelic BSS, ~50% were initially misdiagnosed, mostly as having immune thrombocytopenia, with almost all receiving steroids or intravenous immunoglobulin, and several a splenectomy. Not all had severe bleeding symptoms. This is compounded by the compromised accuracy of both the platelet count and size rendered by automated counters in the presence of large platelets. A mandatory quick look at the blood smear may suggest a macrothrombocytopenia, even if the automated rendition of the mean platelet volume is not striking.

From a biological perspective, although 1 functional phenotype of the abnormal platelet GPIb-IX-V expression (altered platelet interaction with VWF and agglutination with ristocetin) is easy to articulate, less is known regarding the effect on megakaryocyte biology that culminates in altered platelet structure, number, and production. The GPIb-IX-V complex is implicated in late megakaryopoiesis, proplatelet formation, and platelet production. How does the interaction of GPIb-IX-V with VWF regulate platelet biogenesis? Studies with variants of GPIBA and GP1BB provide exciting opportunities.

These studies of Sivapalaratnam et al shed new light on the GPIbβ moiety and advance the parsing of the subunits of platelet GPIb-IX-V complex. Hopefully, similar studies will unravel the effects of monoallelic variants of GP9 and the mystery surrounding the remaining member, GPV, which appears silent in interactions with VWF.

Conflict-of-interest disclosure: The authors declare no competing financial interests.
Parsing the repertoire of GPIb-IX-V disorders

A. Koneti Rao and Natthapol Songdej